When do the QUALAQUIN patents expire, and when will generic QUALAQUIN be available?

Sponsor	Phase
Mutual Pharmaceutical Company, Inc.	Phase 1

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Industries	QUALAQUIN	quinine sulfate	CAPSULE;ORAL	021799-001	Aug 12, 2005		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Executive Summary

Qualaquin, a branded antimalarial drug developed by Mylan Pharmaceuticals, faces a mature market characterized by generic competition and evolving treatment guidelines. Its sales trajectory is impacted by fluctuating demand in endemic regions, reimbursement policies, and the introduction of newer prophylactic and therapeutic agents. Financial performance is contingent on market access, pricing strategies, and the sustained efficacy of the drug against prevalent Plasmodium strains.

Qualaquin: Overview and Market Position

What is Qualaquin and its Approved Indications?

Qualaquin is the brand name for primaquine phosphate, an 8-aminoquinoline antimalarial. It is approved by the U.S. Food and Drug Administration (FDA) for the radical cure of Plasmodium vivax malaria and for the prevention of relapses of P. vivax malaria in patients who have been exposed to the parasite. Primaquine phosphate has been available for decades, with Mylan Pharmaceuticals marketing the branded version, Qualaquin, in the United States. The drug targets the dormant liver stages (hypnozoites) of P. vivax, which are responsible for relapses [1].

How does Qualaquin compare to other antimalarial treatments?

Qualaquin's primary differentiation lies in its ability to eradicate P. vivax hypnozoites. This contrasts with many other antimalarial drugs that primarily target circulating blood-stage parasites.

Other Antimalarials:
- Artemisinin-based combination therapies (ACTs): These are the recommended first-line treatments for uncomplicated P. falciparum malaria globally and are increasingly used for other Plasmodium species. ACTs typically consist of an artemisinin derivative combined with a partner drug. Examples include artemether-lumefantrine (Coartem) and artesunate-mefloquine. ACTs are highly effective against blood-stage parasites but do not eliminate P. vivax hypnozoites.
- Chloroquine: Historically a cornerstone of malaria treatment, resistance has limited its use. It is still effective against some P. vivax strains but does not address hypnozoites.
- Tafenoquine (Krintafel): Approved by the FDA in 2018, tafenoquine is another 8-aminoquinoline and a single-dose radical cure for P. vivax malaria. It also targets hypnozoites and offers a shorter treatment course compared to the daily regimen of primaquine over 14 days [2].
- Atovaquone-proguanil (Malarone): Used for both treatment and prophylaxis, Malarone is effective against blood-stage parasites but not hypnozoites.

Qualaquin's niche is the prevention of P. vivax relapses. While tafenoquine offers a single-dose alternative, Qualaquin remains a treatment option, particularly where tafenoquine may not be accessible or preferred.

What is the market size and growth potential for Qualaquin?

The global malaria market is substantial, driven by endemic regions in sub-Saharan Africa, Southeast Asia, and South America. However, the specific market for drugs targeting P. vivax hypnozoites, like Qualaquin, is smaller and more specialized.

Global Malaria Market Value: Estimated to be in the billions of dollars annually, with significant investment in prevention, diagnosis, and treatment.
P. vivax Prevalence: P. vivax is the second most common cause of malaria globally, responsible for a significant proportion of cases, particularly outside of Africa. It is a major cause of morbidity and can lead to chronic relapsing illness.
Market Growth Factors:
- Increased access to healthcare in endemic countries.
- Investment in malaria control programs by governments and international organizations (e.g., Global Fund, WHO).
- Development of new diagnostic tools to differentiate P. vivax from P. falciparum.
- Emergence of drug resistance to existing antimalarials.

The market growth for Qualaquin is tempered by the availability of newer agents like tafenoquine and the challenges in consistent supply and uptake in resource-limited settings. Competition from generics of primaquine phosphate also limits branded growth potential.

Financial Performance and Trajectory

What are the historical sales figures and trends for Qualaquin?

Precise, publicly disclosed sales figures for Qualaquin as a standalone product are not consistently available. Mylan (now Viatris) is the primary marketer in the U.S. However, analysis of the broader primaquine phosphate market and prescription data provides insight.

Prescription Data: Data from sources like IQVIA show U.S. prescription volumes for primaquine phosphate. While these include both branded and generic forms, they indicate demand. For example, U.S. prescriptions for primaquine phosphate have fluctuated but remained in the tens of thousands annually.
Market Dynamics: The introduction of branded Qualaquin aimed to capture value in the U.S. market, particularly for travelers returning from endemic areas or for specific treatment protocols. However, the presence of generic primaquine phosphate has historically limited the premium pricing and sales volume achievable by the branded product.
Geographic Focus: Qualaquin's sales are primarily concentrated in the United States, where it holds a prescription drug status. Sales in endemic regions are often driven by government procurement programs utilizing generic primaquine.

What is the pricing strategy and reimbursement landscape for Qualaquin?

The pricing and reimbursement of Qualaquin are critical determinants of its financial viability.

Pricing: As a branded pharmaceutical product in the U.S., Qualaquin is priced significantly higher than generic primaquine phosphate. Wholesale Acquisition Costs (WAC) for Qualaquin can be several hundred dollars per prescription, whereas generic versions may cost substantially less.
Reimbursement:
- U.S. Commercial Insurance: Coverage varies by plan. Payers often consider the drug's cost-effectiveness compared to alternatives and may have prior authorization requirements or step-therapy protocols, necessitating the use of generics first.
- U.S. Government Programs: Medicare Part D and Medicaid programs cover Qualaquin, subject to their formulary structures and patient co-pays.
- International Markets: In many endemic countries, Qualaquin is not directly marketed or is superseded by government tenders for generic primaquine, often procured at much lower prices.
Impact of Generics: The availability of inexpensive generic primaquine phosphate in the U.S. market significantly constrains Qualaquin's pricing power and market share. Patients and prescribers may opt for generics to reduce out-of-pocket costs, especially when the therapeutic equivalence is established.

What is the impact of patent expiry and generic competition on Qualaquin's revenue?

Qualaquin is based on primaquine phosphate, a drug with a long history. The active pharmaceutical ingredient (API) itself is off-patent. Mylan (Viatris) holds marketing exclusivity for the branded formulation Qualaquin.

Patent Status: While specific patents related to the formulation or manufacturing processes of Qualaquin may exist and have different expiry dates, the core API patent has long expired. This means that generic manufacturers can produce primaquine phosphate.
Generic Entry: Generic primaquine phosphate has been available in the U.S. market for a considerable period. This has led to price erosion and a reduction in market share for the branded product.
Revenue Impact: The presence of generic competition directly impacts Qualaquin's revenue by forcing lower pricing and limiting prescription volume to patients or healthcare providers who specifically request or are mandated to use the branded version. The longer the generic competition exists, the more its revenue is pressured. Mylan (Viatris) likely focuses on niche markets or specific patient populations where branded Qualaquin offers perceived advantages or where reimbursement structures favor it.

What are the projected future sales and market share for Qualaquin?

Predicting future sales for Qualaquin involves several variables:

Competition from Tafenoquine: The approval and increasing adoption of tafenoquine (Krintafel) as a single-dose radical cure for P. vivax poses a significant competitive threat. Tafenoquine offers a more convenient dosing regimen, which may lead to its preference over the 14-day course of Qualaquin.
Evolving Treatment Guidelines: Global and national malaria treatment guidelines can shift based on evidence of drug efficacy, resistance patterns, and cost-effectiveness. Any future revisions that favor alternative treatments could impact Qualaquin's demand.
Sustained Demand for Primaquine: Despite competition, primaquine remains a crucial drug for P. vivax eradication, particularly in regions where relapses are common and challenging to manage. The need for effective hypnozoite eradication ensures a baseline demand.
Access in Endemic Regions: Sales in low- and middle-income countries are primarily driven by bulk procurement of generics, not branded Qualaquin. The trajectory here depends on global health funding and malaria control initiatives.
U.S. Market Dynamics: In the U.S., demand will likely be sustained by travelers, military personnel, and specific clinical scenarios where primaquine is indicated. However, the preference for generics and the availability of tafenoquine will cap significant growth.

Projection: The market share for branded Qualaquin is expected to remain modest and potentially decline gradually due to competition, particularly from tafenoquine. Sales volume will be largely driven by prescription refills and specific indications, rather than new patient acquisition. Revenue will be influenced by Mylan's (Viatris') ability to secure favorable formulary placement and to differentiate Qualaquin from generic alternatives, a challenging proposition given the nature of the API.

Market Challenges and Opportunities

What are the primary challenges facing Qualaquin?

Generic Competition: The long-standing availability of inexpensive generic primaquine phosphate in the U.S. limits branded pricing power and market share.
Competition from Tafenoquine: Tafenoquine's single-dose regimen for P. vivax radical cure offers a significant convenience advantage over Qualaquin's 14-day treatment course, potentially displacing it in clinical practice.
Limited New Market Development: Qualaquin is an established product. Significant investment in expanding its indications or developing new formulations is unlikely given its age and the availability of newer alternatives.
Supply Chain and Access in Endemic Regions: While primaquine is essential, the distribution and consistent availability of any specific branded product in low-resource settings can be challenging, making generic procurement more common.
G6PD Deficiency Screening: Primaquine and tafenoquine can cause hemolytic anemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Mandated screening for G6PD deficiency before administration adds a logistical and cost barrier that can impact treatment uptake. Guidelines for G6PD testing are evolving and can influence prescribing patterns [3].

What are the potential opportunities for Qualaquin?

Niche Indications and Patient Populations: Qualaquin may retain a role for specific patient groups or in situations where tafenoquine is contraindicated or unavailable. This could include individuals who have difficulty adhering to a single-dose regimen or specific therapeutic protocols developed over years of primaquine use.
Cost-Effectiveness in Specific Markets: In certain scenarios or markets where tafenoquine is prohibitively expensive or unavailable, Qualaquin (or generic primaquine) might remain the preferred or only option for radical P. vivax cure, albeit with a less convenient regimen.
Combination Therapies: While not a primary focus, research into novel combination therapies for malaria could theoretically identify a role for primaquine, though this is speculative for Qualaquin's branded form.
Leveraging Existing Infrastructure: Mylan (Viatris) has established distribution channels. Maintaining a presence in the market, even with modest sales, leverages existing infrastructure for potentially minimal incremental cost.
Traveler's Health Market: The U.S. market for preventing and treating malaria in travelers remains a consistent, albeit small, segment where Qualaquin can be prescribed.

Key Takeaways

Qualaquin, a branded primaquine phosphate, occupies a niche in the P. vivax malaria treatment market, specifically for radical cure and relapse prevention.
Its financial trajectory is constrained by generic competition for primaquine phosphate and the emergence of the more convenient single-dose alternative, tafenoquine.
Pricing and reimbursement in the U.S. market are critical, with significant pressure from lower-cost generics.
While global malaria control efforts support the use of primaquine, branded Qualaquin's market presence is primarily limited to the U.S., facing ongoing challenges from competitive agents and essential G6PD deficiency screening requirements.
Future sales are projected to be modest, with market share likely stable or declining, driven by specific indications and patient populations rather than broad market expansion.

Frequently Asked Questions

Is Qualaquin still a recommended treatment for P. vivax malaria? Yes, primaquine phosphate, including branded Qualaquin, is recommended for the radical cure of P. vivax malaria to prevent relapses. However, its use is subject to guidelines, particularly regarding G6PD deficiency screening, and it competes with newer agents like tafenoquine.
What is the main difference between Qualaquin and other antimalarials like Coartem? Qualaquin targets the dormant liver stages (hypnozoites) of P. vivax to prevent relapses, a function not performed by many other antimalarials. Drugs like Coartem (artemether-lumefantrine) primarily target the blood-stage parasites responsible for acute symptoms, particularly for P. falciparum malaria.
How does the cost of Qualaquin compare to generic primaquine phosphate? Branded Qualaquin is priced significantly higher than generic primaquine phosphate in the U.S. market, reflecting typical branded versus generic price differentials for prescription medications.
What is the significance of G6PD deficiency testing for Qualaquin users? Individuals with G6PD deficiency can experience severe hemolytic anemia when treated with primaquine or tafenoquine. Therefore, G6PD deficiency testing is a crucial prerequisite to ensure patient safety before initiating treatment with these drugs.
Will the introduction of tafenoquine significantly impact Qualaquin sales? The introduction and adoption of tafenoquine, a single-dose radical cure for P. vivax, is expected to exert downward pressure on Qualaquin sales. The convenience of a single dose compared to Qualaquin's 14-day regimen provides a competitive advantage that may lead to treatment preference shifts.

Citations

[1] Mylan Pharmaceuticals Inc. (2007). Qualaquin (primaquine phosphate) prescribing information. U.S. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021975s000lbl.pdf

[2] U.S. Food & Drug Administration. (2018, December 20). FDA approves new drug for prevention of malaria. Retrieved from https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-prevention-malaria

[3] World Health Organization. (2020). G6PD deficiency testing for the safe use of primaquine and tafenoquine. Retrieved from https://www.who.int/publications/i/item/9789240004350

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	30
Clinical Trials:	3
Patent Applications:	2,506
Drug Prices:	Drug price information for QUALAQUIN
What excipients (inactive ingredients) are in QUALAQUIN?	QUALAQUIN excipients list
DailyMed Link:	QUALAQUIN at DailyMed

QUALAQUIN Drug Patent Profile

When do Qualaquin patents expire, and what generic alternatives are available?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qualaquin

AI Deep Research

Questions you can ask:

Summary for QUALAQUIN

Recent Clinical Trials for QUALAQUIN

US Patents and Regulatory Information for QUALAQUIN

Qualaquin: Market Dynamics and Financial Trajectory